<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Elevated plasma levels of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> (<z:chebi fb="0" ids="17230">Hcy</z:chebi>) are a risk factor for systemic <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">vascular diseases</z:e>, <z:hpo ids='HP_0001297'>stroke</z:hpo> and vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In recent years, increasing <z:chebi fb="0" ids="17230">Hcy</z:chebi> levels have been detected in <z:e sem="disease" ids="C1112108" disease_type="Disease or Syndrome" abbrv="">neurological disorders</z:e> that are not vascular in origin including <z:e sem="disease" ids="C0002395" disease_type="Disease or Syndrome" abbrv="SDAT">Alzheimer's Disease</z:e> and <z:hpo ids='HP_0100022'>movement disorders</z:hpo> (MD) such as <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">idiopathic Parkinson's Disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>), <z:e sem="disease" ids="C0020179" disease_type="Disease or Syndrome" abbrv="HD">Huntington's Disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) and primary <z:hpo ids='HP_0001332'>dystonia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> (HHcy) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> results from <z:chebi fb="3" ids="15765">L-Dopa</z:chebi> administration and its O-methylation dependent from <z:chebi fb="5" ids="18135">catechol</z:chebi>-O-methyltransferase and may be implicated in the development of motor complications and non-motor symptoms, such as <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In a recent study, HHcy has been evidenced in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> patients, compared to controls </plain></SENT>
<SENT sid="4" pm="."><plain>Because mutated Huntington protein influences <z:chebi fb="0" ids="17230">Hcy</z:chebi> metabolism by modulating <z:chebi fb="0" ids="17755">cystathionine</z:chebi>-beta-synthase activity, <z:chebi fb="0" ids="17230">Hcy</z:chebi> could represent a biological marker of <z:hpo ids='HP_0002180'>neurodegeneration</z:hpo> and could explain the leading role of cardiovascular and cerebrovascular diseases as causes of <z:hpo ids='HP_0011420'>death</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, several cases of <z:hpo ids='HP_0002156'>homocystinuria</z:hpo> associated with <z:hpo ids='HP_0001332'>dystonia</z:hpo>, and some recent reports of elevated <z:chebi fb="0" ids="17230">Hcy</z:chebi> in patients with primary <z:hpo ids='HP_0003581'>adult onset</z:hpo> <z:hpo ids='HP_0001332'>dystonia</z:hpo> have been published </plain></SENT>
<SENT sid="6" pm="."><plain>Increased <z:chebi fb="0" ids="17230">Hcy</z:chebi> plasma levels may have important implications in patients affected by these basal ganglia disturbances, by exerting neurotoxic effects, contributing to <z:mp ids='MP_0002205'>neurotransmitter imbalance</z:mp> in motor circuits, and increasing the risk for vascular insults and <z:e sem="disease" ids="C0338656" disease_type="Mental or Behavioral Dysfunction" abbrv="">cognitive dysfunctions</z:e> </plain></SENT>
</text></document>